2024 (1 POST)
Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693 . ISPOR Europe 2024, November 2024.
View Abstract
Publication: Abstracts and Presentations
2023 (4 POSTS)
Bean K, Miller B, Jensen I , Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Miller B, Jensen I , Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285 . ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Olaye A, Miller B, Jensen I , Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408 . ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258 .
Publication: Abstracts and Presentations
2022 (1 POST)
Pang F, Dean R, Jensen I , Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24 . ISPOR 2022.
View Abstract